MicroRNA-based methods and assays for osteosarcoma
US9322016B2 · kind B2 · utility
2Cited by
0References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 7, 2012 |
| Grant date | Apr 26, 2016 |
| Priority date | — |
| Expiry date | Sep 21, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/178
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.